The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts : Mechanisms of Action and Differential Racial Effects
Joint Authors
Akter, Tanjina
Bogatkevich, Galina S.
Highland, Kristin B.
Silver, Richard M.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-11-01
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
We present novel data demonstrating that the expression of PPARγ is reduced in lung fibroblasts from black SSc-ILD patients as compared to white patients.
Activating PPARγ with the agonist rosiglitazone increased the expression of MMP-1 and inhibited collagen type I in lung fibroblasts isolated from white, but not black, SSc-ILD patients.
Blocking the c-Met receptor abolishes rosiglitazone's effects on collagen and MMP-1 in lung fibroblasts isolated from white SSc-ILD patients, while augmenting the expression of the c-Met receptor in fibroblasts from black SSc-ILD patients replicates the effects of rosiglitazone seen in whites.
We conclude that PPARγ agonists warrant consideration as potential antifibrotic drugs in patients with SSc-ILD.
Differential therapeutic effects might be anticipated especially relative to racial differences and the functional expression of the c-Met receptor.
American Psychological Association (APA)
Bogatkevich, Galina S.& Highland, Kristin B.& Akter, Tanjina& Silver, Richard M.. 2011. The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts : Mechanisms of Action and Differential Racial Effects. Pulmonary Medicine،Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-480268
Modern Language Association (MLA)
Bogatkevich, Galina S.…[et al.]. The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts : Mechanisms of Action and Differential Racial Effects. Pulmonary Medicine No. 2012 (2012), pp.1-9.
https://search.emarefa.net/detail/BIM-480268
American Medical Association (AMA)
Bogatkevich, Galina S.& Highland, Kristin B.& Akter, Tanjina& Silver, Richard M.. The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts : Mechanisms of Action and Differential Racial Effects. Pulmonary Medicine. 2011. Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-480268
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-480268